EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
Two Presentations Highlighting YUTIQ™ to be Presented at the 2019
Data from Two Phase 3 Studies of DEXYCU™ to be presented at the 2019
2019
An oral presentation and a poster highlighting long-term, 36- and 24-month data of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg, the Company’s three-year micro-insert for chronic non-infectious uveitis affecting the posterior segment of the eye, have been accepted for presentation at the ARVO 2019 Annual Meeting being held
Oral Presentation:
Title: Treatment of Non-infectious Uveitis that Affects the Posterior Segment with a Single Intravitreal Fluocinolone Acetonide Insert (FAi) – 3-year Results
Presenter:
Session Title: Uveitis Clinical Epidemiology and Therapeutics
Data and Time:
Poster Presentation:
Title: Minimizing Recurrences of Ocular Inflammation and Need for Adjunctive Treatment of Non-infectious Posterior Uveitis (NIPU) during the 2 Years Following Treatment with a Single 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi)
Session Title: Uveitis and Scleritis - Clinical Therapeutics and Checkpoint Inhibitors
Data and Time:
2019
A poster highlighting DEXYCU™ (dexamethasone intraocular suspension) 9%, the Company’s single dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation following cataract surgery, has been accepted for presentation at the ASCRS ASOA 2019 Annual Meeting being held
Title: Effect of Dexamethasone Intraocular Suspension 9% on IOP after Cataract Surgery: Results of Two Phase 3 Studies
Session Title: SPS-301 Inflammation, Pain, Infection
Data and Time:
About YUTIQ™
YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, and was approved by the FDA on October 12, 2018. A link to the full product label is available on the EyePoint Pharma website at: www.eyepointpharma.com/wp-content/uploads/2019/01/YUTIQ-USPI-20181120.pdf.
About DEXYCU™
DEXYCUTM (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation and was approved by the
About
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the closing of the proposed offering, as well as the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes satisfaction of the customary closing conditions to the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility, the impact of general business and economic conditions, the expected gross proceeds from the offering and the intended use of proceeds of the offering. More detailed information on these and additional factors that could affect EyePoint’s actual results are described in EyePoint’s filings with the
Contacts
Investors:
(646) 368-8014
kimberly@argotpartners.com
(617) 340-6075
joseph@argotpartners.com
Media:
(201) 476-0322
tom@tomgibsoncommunications.com
Source: EyePoint Pharmaceuticals, Inc.
